These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 27206057)

  • 1. Serum levels of hepatocyte growth factor as a potential tumor marker in patients with malignant melanoma.
    Hügel R; Muendlein A; Volbeding L; Drexel H; Richtig E; Wehkamp U; Painsi C; Lange-Asschenfeldt B; Hauschild A; Egberts F
    Melanoma Res; 2016 Aug; 26(4):354-60. PubMed ID: 27206057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.
    Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A
    Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in Stage III-IV malignant melanoma.
    Bánfalvi T; Boldizsár M; Gergye M; Gilde K; Kremmer T; Ottó S
    Pathol Oncol Res; 2002; 8(3):183-7. PubMed ID: 12515998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma.
    Mårtenson ED; Hansson LO; Nilsson B; von Schoultz E; Månsson Brahme E; Ringborg U; Hansson J
    J Clin Oncol; 2001 Feb; 19(3):824-31. PubMed ID: 11157036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogenous S-100B protein expression patterns in malignant melanoma and association with serum protein levels.
    Bánfalvi T; Udvarhelyi N; Orosz Z; Gergye M; Gilde K; Tímár J
    Oncology; 2003; 64(4):374-9. PubMed ID: 12759535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma.
    Kubo Y; Fukushima S; Inamori Y; Tsuruta M; Egashira S; Yamada-Kanazawa S; Nakahara S; Tokuzumi A; Miyashita A; Aoi J; Kajihara I; Tomita Y; Wakamatsu K; Jinnin M; Ihn H
    J Dermatol Sci; 2019 Jan; 93(1):33-40. PubMed ID: 30318169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S-100B: a stronger prognostic biomarker than LDH in stage IIIB-C melanoma.
    Wevers KP; Kruijff S; Speijers MJ; Bastiaannet E; Muller Kobold AC; Hoekstra HJ
    Ann Surg Oncol; 2013 Aug; 20(8):2772-9. PubMed ID: 23512078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of serum S-100B in malignant melanoma.
    Andrés R; Mayordomo JI; Zaballos P; Rodino J; Isla D; Escudero P; Elosegui L; Filipovich E; Saenz A; Polo E; Tres A
    Tumori; 2004; 90(6):607-10. PubMed ID: 15762365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of pre operative S-100B and SUV in clinically stage III melanoma patients undergoing therapeutic lymph node dissection.
    Kruijff S; Bastiaannet E; Speijers MJ; Kobold AC; Brouwers AH; Hoekstra HJ
    Eur J Surg Oncol; 2011 Mar; 37(3):225-32. PubMed ID: 21277729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse.
    Egberts F; Hitschler WN; Weichenthal M; Hauschild A
    Melanoma Res; 2009 Feb; 19(1):31-5. PubMed ID: 19104452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of S-100B to evaluate therapy effects during bevacizumab induction treatment in AJCC stage III melanoma.
    Kruijff S; Bastiaannet E; Brouwers AH; Nagengast WB; Speijers MJ; Suurmeijer AJ; Hospers GA; Hoekstra HJ
    Ann Surg Oncol; 2012 Feb; 19(2):620-6. PubMed ID: 21861214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Laboratory markers of melanoma progression].
    Bánfalvi T; Edesné MB; Gergye M; Udvarhelyi N; Orosz Z; Gilde K; Kremmer T; Ottó S; Tímár J
    Magy Onkol; 2003; 47(1):89-104. PubMed ID: 12704461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of multiple serum markers in advanced melanoma.
    Díaz-Lagares A; Alegre E; Arroyo A; González-Cao M; Zudaire ME; Viteri S; Martín-Algarra S; González A
    Tumour Biol; 2011 Dec; 32(6):1155-61. PubMed ID: 21858537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High GDF-15 Serum Levels Independently Correlate with Poorer Overall Survival of Patients with Tumor-Free Stage III and Unresectable Stage IV Melanoma.
    Weide B; Schäfer T; Martens A; Kuzkina A; Uder L; Noor S; Garbe C; Harter PN; Mittelbronn M; Wischhusen J
    J Invest Dermatol; 2016 Dec; 136(12):2444-2452. PubMed ID: 27705749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients.
    Smit LH; Korse CM; Hart AA; Bonfrer JM; Haanen JB; Kerst JM; Nieweg OE; de Gast GC
    Eur J Cancer; 2005 Feb; 41(3):386-92. PubMed ID: 15691637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S-100B protein and melanoma inhibitory activity protein in uveal melanoma screening. A comparison with liver function tests.
    Missotten GS; Korse CM; van Dehn C; Linders TC; Keunen JE; Jager MJ; Bonfrer JM
    Tumour Biol; 2007; 28(2):63-9. PubMed ID: 17264538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients.
    Toiyama Y; Miki C; Inoue Y; Okugawa Y; Tanaka K; Kusunoki M
    Int J Cancer; 2009 Oct; 125(7):1657-62. PubMed ID: 19569242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The predictive power of serum S-100B for non-sentinel node positivity in melanoma patients.
    Damude S; Hoekstra HJ; Bastiaannet E; Muller Kobold AC; Kruijff S; Wevers KP
    Eur J Surg Oncol; 2016 Apr; 42(4):545-51. PubMed ID: 26831006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of serum 5-S-CD and S-100B protein levels to monitor the clinical course of malignant melanoma.
    Bánfalvi T; Gilde K; Gergye M; Boldizsár M; Kremmer T; Ottó S
    Eur J Cancer; 2003 Jan; 39(2):164-9. PubMed ID: 12509947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
    Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
    J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.